A review of Peyronie's disease insurance coverage.
Peyronie’s
cross sectional analysis
erectile dysfunction
insurance
Journal
Sexual medicine
ISSN: 2050-1161
Titre abrégé: Sex Med
Pays: England
ID NLM: 101631053
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
28
06
2024
revised:
17
09
2024
accepted:
29
09
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Peyronie's disease (PD) is a fibroproliferative disorder that causes an abnormal curve of the penis resulting in pain, discomfort, and erectile dysfunction with management options including correctional surgery, penile external/internal devices, shock wave therapy (SWT), intralesional Verapamil (IV), and collagenase To investigate the insurance coverage of these treatment options. The authors performed a cross-sectional analysis of the top US insurance policies for coverage of PD. Companies were chosen based on their market share and enrollment. Their policies were identified through a Web-based search and telephone interviews, and the companies' medical necessity criteria were defined. The online policies were then re-examined for interval change 3 years later. There are significant discrepancies for in coverage for the different modalities of Peyronie's treatment. Of the 100 companies examined, only 54% of companies had a policy that directly addressed the treatment coverage for PD. The most covered treatment was CCH injections with 37 companies providing unanimous coverage ( Insurance coverage of PD should be aligned with current medical literature to better increase access to care. This study is limited by the updated policies of insurance companies and future applicability. Additionally, this study assumes that a written policy will provide coverage and may overestimate the actual extent of coverage. Finally, this study only addressed some of the common treatment options of PD and did not expand on all possible treatment options. Differing rates for modalities of treatment may present a barrier for patients to receive individualized and adequate treatment for PD.
Sections du résumé
Background
UNASSIGNED
Peyronie's disease (PD) is a fibroproliferative disorder that causes an abnormal curve of the penis resulting in pain, discomfort, and erectile dysfunction with management options including correctional surgery, penile external/internal devices, shock wave therapy (SWT), intralesional Verapamil (IV), and collagenase
Aim
UNASSIGNED
To investigate the insurance coverage of these treatment options.
Methods
UNASSIGNED
The authors performed a cross-sectional analysis of the top US insurance policies for coverage of PD. Companies were chosen based on their market share and enrollment. Their policies were identified through a Web-based search and telephone interviews, and the companies' medical necessity criteria were defined. The online policies were then re-examined for interval change 3 years later.
Outcomes
UNASSIGNED
There are significant discrepancies for in coverage for the different modalities of Peyronie's treatment.
Results
UNASSIGNED
Of the 100 companies examined, only 54% of companies had a policy that directly addressed the treatment coverage for PD. The most covered treatment was CCH injections with 37 companies providing unanimous coverage (
Clinical Implications
UNASSIGNED
Insurance coverage of PD should be aligned with current medical literature to better increase access to care.
Strengths & Limitations
UNASSIGNED
This study is limited by the updated policies of insurance companies and future applicability. Additionally, this study assumes that a written policy will provide coverage and may overestimate the actual extent of coverage. Finally, this study only addressed some of the common treatment options of PD and did not expand on all possible treatment options.
Conclusion
UNASSIGNED
Differing rates for modalities of treatment may present a barrier for patients to receive individualized and adequate treatment for PD.
Identifiants
pubmed: 39450208
doi: 10.1093/sexmed/qfae071
pii: qfae071
pmc: PMC11500605
doi:
Types de publication
Journal Article
Langues
eng
Pagination
qfae071Informations de copyright
Published by Oxford University Press on behalf of The International Society for Sexual Medicine 2024.
Déclaration de conflit d'intérêts
The authors have no conflict of interests to disclose.